Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63


Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS.

Cancer Cell. 2012 Feb 14;21(2):227-39. doi: 10.1016/j.ccr.2011.12.024.


mTOR as a therapeutic target in patients with gastric cancer.

Al-Batran SE, Ducreux M, Ohtsu A.

Int J Cancer. 2012 Feb 1;130(3):491-6. doi: 10.1002/ijc.26396. Epub 2011 Oct 5. Review.


A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.

Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, Sutton L, Hurwitz HI.

Oncologist. 2011;16(8):1131-7. doi: 10.1634/theoncologist.2011-0078. Epub 2011 Jul 27.


Interleukin-6 as a therapeutic target in human ovarian cancer.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR.

Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27.


Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.

Mankan AK, Greten FR.

Expert Opin Investig Drugs. 2011 Sep;20(9):1263-75. doi: 10.1517/13543784.2011.601739. Epub 2011 Jul 14. Review.


Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.

Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G, Poussin K, Zucman-Rossi J.

J Exp Med. 2011 Jul 4;208(7):1359-66. doi: 10.1084/jem.20110283. Epub 2011 Jun 20.


Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Wander SA, Hennessy BT, Slingerland JM.

J Clin Invest. 2011 Apr;121(4):1231-41. doi: 10.1172/JCI44145. Epub 2011 Apr 1. Review.


PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

Hollander MC, Blumenthal GM, Dennis PA.

Nat Rev Cancer. 2011 Apr;11(4):289-301. doi: 10.1038/nrc3037. Review. Erratum in: Nat Rev Cancer. 2011 Jun;11(6):458.


High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics.

Carvalho CM, Chang J, Lucas JE, Nevins JR, Wang Q, West M.

J Am Stat Assoc. 2008 Dec 1;103(484):1438-1456.


Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice.

Chen C, Liu Y, Liu Y, Zheng P.

J Clin Invest. 2010 Nov;120(11):4091-101. doi: 10.1172/JCI43873. Epub 2010 Oct 25. Erratum in: J Clin Invest. 2010 Dec 1;120(12):4583.


More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer.

Putoczki T, Ernst M.

J Leukoc Biol. 2010 Dec;88(6):1109-17. doi: 10.1189/jlb.0410226. Epub 2010 Jul 7. Review.


Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy.

Palmieri M, Nowell CJ, Condron M, Gardiner J, Holmes AB, Desai J, Burgess AW, Catimel B.

Anal Biochem. 2010 Nov 1;406(1):41-50. doi: 10.1016/j.ab.2010.06.033. Epub 2010 Jun 25.


Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?

Jarnicki A, Putoczki T, Ernst M.

Cell Div. 2010 May 17;5:14. doi: 10.1186/1747-1028-5-14.


The emerging mechanisms of isoform-specific PI3K signalling.

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B.

Nat Rev Mol Cell Biol. 2010 May;11(5):329-41. doi: 10.1038/nrm2882. Epub 2010 Apr 9. Review.


Airway PI3K pathway activation is an early and reversible event in lung cancer development.

Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, Cooper K, Walker D, McWilliams A, Liu G, Szabo E, Brody J, Massion PP, Lenburg ME, Lam S, Bild AH, Spira A.

Sci Transl Med. 2010 Apr 7;2(26):26ra25. doi: 10.1126/scitranslmed.3000251.


Immunity, inflammation, and cancer.

Grivennikov SI, Greten FR, Karin M.

Cell. 2010 Mar 19;140(6):883-99. doi: 10.1016/j.cell.2010.01.025. Review.


Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.

Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A.

J Clin Oncol. 2010 Apr 10;28(11):1904-10. doi: 10.1200/JCO.2009.26.2923. Epub 2010 Mar 15.


Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.

Agarwala SS, Case S.

Oncologist. 2010;15(3):236-45. doi: 10.1634/theoncologist.2009-0141. Epub 2010 Mar 9. Review.


Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.

Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M.

Cell. 2010 Jan 22;140(2):197-208. doi: 10.1016/j.cell.2009.12.052.


A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis.

Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y, Orlofsky A, Liu Q, Hume DA, Pollard JW, Augenlicht L, Lin EY.

Am J Pathol. 2010 Feb;176(2):952-67. doi: 10.2353/ajpath.2010.090622. Epub 2009 Dec 30.

Supplemental Content

Support Center